CCG
VTYX

Catalina Capital Group’s Ventyx Biosciences VTYX Stock Holding History

Catalina Capital Group’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,456
Closed -$25.1K – 367
2024
Q4 		$25.1K Buy
+11,456
New +$26K 0.01% 361

Other funds holding VTYX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalina Capital Group's VTYX Position: Q1 2025 in Review

Catalina Capital Group sold out of Ventyx Biosciences (VTYX) in Q1 2025, closing a stake of 11,456 shares — an estimated $25.1K sold.

Catalina Capital Group first reported a position in VTYX in Q4 2024 and held it in 1 quarter. The position peaked at $25.1K in Q4 2024. 116 funds tracked by Wall St. Rank hold VTYX as of Q1 2025.

  • Catalina Capital Group reported no remaining Ventyx Biosciences position as of Q1 2025 after selling out during the quarter.
  • Catalina Capital Group sold 11,456 Ventyx Biosciences shares in Q1 2025, an estimated $25.1K.
  • Catalina Capital Group first reported a position in Ventyx Biosciences in Q4 2024 and held it in 1 quarter.
  • Catalina Capital Group's Ventyx Biosciences position peaked at $25.1K in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2025.

Based on Catalina Capital Group's 13F filing for Q1 2025, filed 21 Apr 2025.